

John Stagg

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1357141/john-stagg-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59
papers

5,738
citations

35
h-index

63
g-index

63
ext. papers

7,154
ext. citations

9.6
avg, IF

6.07
L-index

#	Paper	IF	Citations
59	The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. <i>Immunological Reviews</i> , 2017 , 276, 121-144	11.3	414
58	Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 1547-52	11.5	413
57	Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 7142-7	11.5	334
56	CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 11091-6	11.5	303
55	CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. <i>Cancer Research</i> , 2011 , 71, 2892-900	10.1	297
54	Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. <i>Clinical Cancer Research</i> , 2013 , 19, 5626-35	12.9	293
53	CD73: a potent suppressor of antitumor immune responses. <i>Trends in Immunology</i> , 2012 , 33, 231-7	14.4	253
52	Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 14711-6	11.5	244
51	Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. <i>Science</i> , 2020 , 369, 1481-1489	33.3	233
50	Targeting cancer-derived adenosine: new therapeutic approaches. <i>Cancer Discovery</i> , 2014 , 4, 879-88	24.4	199
49	Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses. <i>Cancer Immunology Research</i> , 2015 , 3, 506-17	12.5	198
48	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. <i>Journal of Clinical Investigation</i> , 2017 , 127, 929-941	15.9	183
47	Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. <i>Cancer Research</i> , 2014 , 74, 3652-8	10.1	178
46	CD73-deficient mice are resistant to carcinogenesis. <i>Cancer Research</i> , 2012 , 72, 2190-6	10.1	156
45	Immunosuppressive activities of adenosine in cancer. <i>Current Opinion in Pharmacology</i> , 2016 , 29, 7-16	5.1	156
44	CD73 is associated with poor prognosis in high-grade serous ovarian cancer. <i>Cancer Research</i> , 2015 , 75, 4494-503	10.1	142
43	Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. <i>Journal of Clinical Investigation</i> , 2019 , 129, 1785-1800	15.9	125

42	CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 158-66	12.9	121
41	Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. <i>Therapeutic Advances in Medical Oncology</i> , 2013 , 5, 169-81	5.4	121
40	Anti-CD73 therapy impairs tumor angiogenesis. <i>International Journal of Cancer</i> , 2014 , 134, 1466-73	7.5	108
39	The adenosine pathway in immuno-oncology. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 611-629	19.4	101
38	Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. <i>Cancer Research</i> , 2016 , 76, 4372-82	10.1	94
37	Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. <i>Annals of Oncology</i> , 2018 , 29, 1056-1062	10.3	92
36	CD73-adenosine: a next-generation target in immuno-oncology. <i>Immunotherapy</i> , 2016 , 8, 145-63	3.8	82
35	Mesenchymal stem cells in cancer. <i>Stem Cell Reviews and Reports</i> , 2008 , 4, 119-24	6.4	81
34	Targeting the CD73-adenosine axis in immuno-oncology. <i>Immunology Letters</i> , 2019 , 205, 31-39	4.1	73
33	From cancer immunosurveillance to cancer immunotherapy. <i>Immunological Reviews</i> , 2007 , 220, 82-101	11.3	70
32	Targeting A2 adenosine receptors in cancer. <i>Immunology and Cell Biology</i> , 2017 , 95, 333-339	5	65
31	CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. <i>Cancer Research</i> , 2017 , 77, 5652-5663	10.1	64
30	CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. <i>Journal of Biomedicine and Biotechnology</i> , 2012 , 2012, 485156		64
29	The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. <i>Biomarkers in Cancer</i> , 2016 , 8, 15-33	7	57
28	Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 708-719	9.7	45
27	On the mechanism of anti-CD39 immune checkpoint therapy 2020 , 8,		42
26	Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 16254-9	11.5	40
25	Targeting the adenosine pathway for cancer immunotherapy. <i>Seminars in Immunology</i> , 2019 , 42, 101304	10.7	37

24	Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2014 , 18, 863-81	6.4	30
23	CD73 plays a protective role in collagen-induced arthritis. <i>Journal of Immunology</i> , 2015 , 194, 2487-92	5.3	27
22	CD73-adenosine reduces immune responses and survival in ovarian cancer patients. <i>Oncolmmunology</i> , 2016 , 5, e1127496	7.2	27
21	The double-edge sword effect of anti-CD73 cancer therapy. <i>Oncolmmunology</i> , 2012 , 1, 217-218	7.2	22
20	Poly:I:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors. <i>Cancer Research</i> , 2017 , 77, 312-319	10.1	21
19	Co-blockade of immune checkpoints and adenosine A receptor suppresses metastasis. <i>Oncolmmunology</i> , 2014 , 3, e958952	7.2	18
18	NK cell-based cancer immunotherapy. <i>Drug News and Perspectives</i> , 2007 , 20, 155-63		17
17	Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody. <i>Leukemia</i> , 2020 , 34, 2708-2721	10.7	14
16	1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer. <i>Science Advances</i> , 2021 , 7,	14.3	13
15	Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?. <i>Breast Care</i> , 2012 , 7, 267-72	2.4	11
14	Adenosine A2a receptor promotes lymphangiogenesis and lymph node metastasis. <i>Oncolmmunology</i> , 2019 , 8, 1601481	7.2	10
13	WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors. <i>Oncolmmunology</i> , 2019 , 8, e1581545	7.2	9
12	Prognostic value of CD73 expression in resected colorectal cancer liver metastasis. <i>Oncolmmunology</i> , 2020 , 9, 1746138	7.2	6
11	High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer 2021 , 9,		6
10	Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies. <i>Methods in Molecular Biology</i> , 2016 , 1458, 159-77	1.4	5
9	The effect of ultrasound pulse length on microbubble cavitation induced antibody accumulation and distribution in a mouse model of breast cancer. <i>Nanotheranostics</i> , 2020 , 4, 256-269	5.6	5
8	Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays. <i>Methods in Enzymology</i> , 2019 , 629, 269-289	1.7	3
7	NR4A Expression by Human Marginal Zone B-Cells. <i>Antibodies</i> , 2019 , 8,	7	3

6	CD73-A2a adenosine receptor axis promotes innate B cell antibody responses to pneumococcal polysaccharide vaccination. <i>PLoS ONE</i> , 2018 , 13, e0191973	3.7	2
5	Abstract 3361: CD73 expression on tumor-infiltrating breast cancer leukocytes 2015 ,		2
4	Prognostic value of CD73 expression in resected colorectal cancer liver metastasis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3584-3584	2.2	2
3	Spatially mapping the immune landscape of melanoma using imaging mass cytometry.. <i>Science Immunology</i> , 2022 , 7, eabi5072	2.8	2
2	Prognostic implications of adaptive immune features in MMR-proficient colorectal liver metastases classified by histopathological growth patterns.. <i>British Journal of Cancer</i> , 2022 ,	8.7	1
1	Immunology and Immunotherapy of Breast Cancer 2015 , 457-470		